804 studies found for:    Open Studies | "Colorectal Neoplasms"
Show Display Options
Rank Status Study
21 Recruiting Cetuximab in Combination With Chemotherapy for the Treatment of Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Liver Neoplasms
Interventions: Drug: Cetuximab;   Drug: chemotherapy of mFOLFOX6 or FOLFIRI
22 Unknown  Recombinant Human Endostatin in Combination With mFOLFOX6 in Patients With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasm
Intervention: Drug: recombinant human endostatin (Endostat)
23 Recruiting Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
Conditions: Colorectal Neoplasms;   Metastatic Disease
Intervention: Drug: Regorafenib
24 Recruiting The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer
Conditions: Colorectal Cancer;   Surgical Resection of the Colorectal Tumor
Intervention:
25 Recruiting Direct Improvement of Quality of Life Using a Tailored Pathway With Quality of Life Diagnosis and Therapy: Randomised Trial in Colorectal Cancer Patients
Conditions: Quality of Life;   Colorectal Neoplasms
Interventions: Behavioral: quality of life pathway;   Other: placebo control
26 Recruiting Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
Condition: Colorectal Neoplasms
Interventions: Device: SIR-Spheres;   Drug: Regorafenib
27 Recruiting Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab
Conditions: Colorectal Neoplasms;   Metastatic Disease
Intervention: Drug: Regorafenib
28 Unknown  Collecting Information From Patients and Family Members With Hereditary Colorectal Cancer Syndromes or Who Are at High Risk of Developing Colorectal Cancer
Conditions: Colorectal Cancer;   Hereditary Nonpolyposis Colorectal Cancer;   Precancerous Condition
Interventions: Other: study of socioeconomic and demographic variables;   Procedure: evaluation of cancer risk factors;   Procedure: study of high risk factors
29 Recruiting Efficacy of Cap-assisted Chromoendoscopy as a Screening Test for Colorectal Neoplasm Using Web-based Research Network
Condition: Colorectal Neoplasm
Intervention: Device: cap-assisted chromoendoscopy
30 Unknown  Endolaparoscopic Versus Immediate Surgery for Obstructing Colorectal Cancers
Conditions: Colorectal Cancer;   Bowel Obstruction
Intervention: Procedure: Endoscopic stenting followed by elective laparoscopic resection
31 Recruiting Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer
Conditions: Metastatic Pancreatic Cancer;   Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C/NEO-102
32 Recruiting Familial Colorectal Cancer Registry in Hispanics
Condition: Colorectal Cancer
Intervention:
33 Recruiting Colorectal Cancer Registry
Condition: Colorectal Cancer
Intervention: Other: non-interventional
34 Recruiting Assessment of Physical Activity During Therapy With Regorafenib for Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: Regorafenib (Stivarga, BAY73-4506)
35 Recruiting Phase II Study of Maintenance Capecitabine to Treat Resectable Colorectal Cancer
Condition: Colorectal Neoplasms
Intervention: Drug: Capecitabine
36 Recruiting Study of Folic Acid, Calcium and Vitamin D in Preventing Colorectal Polyps and Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: folic acid;   Drug: folic acid  calcium  vitamin D3;   Drug: calcium
37 Recruiting A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: RRx-001;   Drug: Regorafenib
38 Recruiting Nintedanib (BIBF 1120) vs Placebo in Refractory Colorectal Cancer
Condition: Colorectal Neoplasms
Interventions: Drug: Nindetanib (BIBF 1120);   Drug: Placebo;   Drug: BSC
39 Recruiting Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
Condition: Colorectal Neoplasm
Intervention: Drug: Regorafenib (Stivarga, BAY 73-4506)
40 Recruiting New Adjuvant Chemotherapy of Non Resectable Liver Metastasis of Colorectal Cancer Without Bleeding, Obstruction
Conditions: Colorectal Neoplasms;   Neoplasm Metastasis;   Liver Neoplasms;   Chemotherapy; Maternal, Affecting Fetus
Intervention: Drug: chemotherapy ± targeted therapy

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years